Business Wire

CSC to Acquire TCS-Groep in the Netherlands

4.11.2019 16:00:00 EET | Business Wire | Press release

Share

CSC, a world leader in global business, legal, tax, and digital brand services, is pleased to announce that it has signed a definitive agreement to acquire TCS-Groep (TCS), a Netherlands-based service provider for alternative investment funds (AIFs).

TCS offers fund administration and depositary services for alternative asset managers with a focus on real estate, private equity, private debt, and social impact funds, and manages more than €6,5 billion in assets on behalf of its clients. The deal is subject to regulatory approval in the Netherlands.

“We’re delighted to welcome TCS to CSC as part of our long-term strategy to develop the European market by offering international clients our suite of fund administration, capital markets, and depositary services,” says CSC Senior Vice President John Hebert. “TCS has an impressive track record and similar service-oriented culture to our own. The combined offerings and shared reputation for high-quality client service create a unique offering in the marketplace.”

The acquisition of this Netherlands based business extends CSC’s capabilities for global financial market (GFM) clients and gives it a physical presence in another leading European financial center. CSC’s other European GFM offices are in London, Luxembourg, and Dublin. The acquisition follows several strategic hires and investments CSC made in 2019, including the organic recruitment and set-up of its fund administration business in the U.S. and APAC markets. With this acquisition, Liam McHugh, managing director, will relocate to Dublin to oversee CSC’s fund administration business in Europe.

“Beyond extending our capabilities in Europe, this acquisition reinforces our competitive advantage of being a privately held and independent service provider,” says Hebert. “Our long-term stability and client-centric approach is highly valued by funds clients and makes for a strong cultural fit between our respective organizations.”

TCS was founded in 1991 and is headquartered in Maarsbergen, Netherlands. TCS currently has 26 staff across two offices who will join CSC as part of the acquisition. TCS provides back office, compliance, accounting, tax, representation, and domiciliation services to funds based in the Netherlands. And in addition, TCS is the largest non-banking depositary in the Netherlands.

“Becoming part of CSC gives us the ideal platform to further accelerate our success in building the highest quality fund services business in the Netherlands. We are excited to partner with a firm that has an international footprint and the same commitment to service excellence that our clients have come to expect,” says Birgitte van den Broek, CEO of TCS-Groep. “We carefully selected our partner, and this represents the ideal outcome for both our clients and employees. Our clients will continue to receive our personalized services from their existing client service teams, and both our clients and employees will benefit from the extended knowledge base now accessible via CSC.”

Financial terms were not announced. Pepper Hamilton and Houthoff served as legal advisor to CSC. PhiDelphi Corporate Finance acted as sole financial advisor to TCS-Groep and JanssenBroekhuysen provided legal advice.

About CSC

CSC is a leading provider of specialized administration services to alternative asset managers across a range of fund strategies, capital markets participants in both public and private markets, and corporations requiring fiduciary and governance support. We are the unwavering partner for 90% of the Fortune 500®, nearly 10,000 law firms, and more than 3,000 financial institutions. CSC’s Global Financial Markets professionals are located in key financial centers across the U.S., Europe, and Asia-Pacific. We are a global company capable of conducting transactions wherever our clients are―and we accomplish that by deploying experts in every business we serve. For more information about CSC’s services, visit cscgfm.com.

About TCS-Groep

TCS is a leading and reputable service provider in the Netherlands that offers fund-administrative and depositary services to asset managers of alternative investments. Services by TCS are characterized by long-term customer relationships, a stable workforce and first in class systems. While asset managers can concentrate on their core tasks, TCS assures smooth and compliant operations on the background. TCS takes great pride in being the largest non-banking depositary service provider in the Netherlands; as a depositary TCS actively communicates with its clients so as to add real value to its operations, while securing proper fulfilment of all legal requirements. TCS holds licenses from the Dutch Central Bank (DNB) as well as from the Authority Financial Markets (AFM). For more information about TCS’s services, visit www.tcs-groep.nl.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Laura Crozier
Public Relations Manager
(302) 636-5400 x. 65526
CSC® News Room

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye